Cowen and Company cut shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from an outperform rating to a market perform rating in a research note published on Friday. Cowen and Company currently has $9.00 price objective on the stock.

Analyst Recommendations for Raptor Pharmaceutical Corp. (NASDAQ:RPTP)

RPTP has been the topic of several other research reports. FBR & Co reiterated a hold rating on shares of Raptor Pharmaceutical Corp. in a research note on Thursday, September 8th. Zacks Investment Research upgraded shares of Raptor Pharmaceutical Corp. from a hold rating to a buy rating and set a $7.50 price target on the stock in a research note on Thursday, August 11th. Wedbush restated a neutral rating and issued a $4.00 target price (down from $9.00) on shares of Raptor Pharmaceutical Corp. in a report on Monday, September 12th. Finally, Citigroup Inc. downgraded shares of Raptor Pharmaceutical Corp. from a buy rating to a neutral rating and boosted their target price for the stock from $6.00 to $8.00 in a report on Monday, August 8th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $7.93.

Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) opened at 8.97 on Friday. The stock’s market capitalization is $765.19 million. Raptor Pharmaceutical Corp. has a one year low of $2.94 and a one year high of $8.99. The firm has a 50-day moving average of $7.41 and a 200 day moving average of $5.71.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business had revenue of $32.05 million for the quarter, compared to analysts’ expectations of $28.52 million. Raptor Pharmaceutical Corp. had a negative net margin of 79.29% and a negative return on equity of 66.67%. The business’s quarterly revenue was up 37.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.17) EPS. On average, equities research analysts predict that Raptor Pharmaceutical Corp. will post ($0.90) EPS for the current year.

A number of institutional investors have recently modified their holdings of the stock. Sarissa Capital Management LP increased its position in shares of Raptor Pharmaceutical Corp. by 5.5% in the second quarter. Sarissa Capital Management LP now owns 2,875,000 shares of the company’s stock valued at $15,438,000 after buying an additional 150,000 shares during the last quarter. UBS Oconnor LLC increased its position in shares of Raptor Pharmaceutical Corp. by 277.4% in the second quarter. UBS Oconnor LLC now owns 71,100 shares of the company’s stock valued at $382,000 after buying an additional 52,262 shares during the last quarter. Allianz Asset Management AG purchased a new position in shares of Raptor Pharmaceutical Corp. during the second quarter valued at approximately $1,935,000. Ghost Tree Capital LLC purchased a new position in shares of Raptor Pharmaceutical Corp. during the second quarter valued at approximately $3,222,000. Finally, State Street Corp increased its position in shares of Raptor Pharmaceutical Corp. by 42.4% in the second quarter. State Street Corp now owns 1,947,089 shares of the company’s stock valued at $10,454,000 after buying an additional 580,140 shares during the last quarter. Institutional investors own 54.91% of the company’s stock.

Raptor Pharmaceutical Corp. Company Profile

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

5 Day Chart for NASDAQ:RPTP

Receive News & Ratings for Raptor Pharmaceutical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.